Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Learn from experts about the monitoring and management recommendations for corneal events associated with antibody&ndash drug conjugates used to treat patients with cancer. Review expert insights in a clinical commentary along with downloadable slides and on-demand webcast adapted from a live CCO webinar.

Share

Program Content

Activities

Ocular AEs with ADCs
Ocular Toxicity Associated With Antibody–Drug Conjugates: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: January 31, 2022

Expires: January 30, 2023

Activities

ADCs and Ocular Toxicity
Important Considerations for Monitoring and Managing Ocular Toxicities With Antibody–Drug Conjugates
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 20, 2022

Expires: January 19, 2023

No activities added yet

Activities

ADCs and the Cornea
Antibody‒Drug Conjugates and the Cornea
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2021

Expires: November 11, 2022

BCMA ADCs in MM
Clinical Case Study: Targeting BCMA With ADCs in MM
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2021

Expires: November 11, 2022

Managing ADC-Associated AEs
Managing ADC-Associated Toxicity in Patients With Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2021

Expires: November 11, 2022

<i>EP</i>: Corneal Toxicity with ADCs
ExpressPoints
Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 29, 2021

Expires: November 28, 2022

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline